WALTHAM, Mass., Nov. 6, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of three posters describing niraparib at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 5-9, 2015, in Boston, Massachusetts. The posters describe the homologous recombination deficiency (HRD) analysis being performed on tumor samples from the ongoing Phase 3 NOVA trial of niraparib in patients with ovarian cancer, in addition to preclinical data demonstrating that niraparib crosses the blood brain barrier in animal models and highlighting potential genetic markers of resistance in animal models of small cell lung cancer.
"We are executing a very comprehensive development program for niraparib, and believe that the emerging profile of this promising candidate warrants expansion to a variety of tumor types, as a monotherapy and in combination with immuno-oncology and other targeted agents," said Mary Lynne Hedley, Ph.D., President and COO of TESARO. "We are very optimistic about the potential of niraparib for patients with ovarian, breast and other cancers, and we look forward to initiating several new trials in the coming months."
Sunday, November 8, 2015, 12:30 PM to 3:30 PM
Homologous recombination deficiency of high grade serous ovarian tumors from the NOVA Phase III clinical study
Abstract: C53, Location: Session C, Hall C-D
Saturday, November 7, 2015, 12:30 PM to 3:30 PM
The PARP inhibitor, niraparib, crosses the blood brain barrier in rodents and is efficacious in a BRCA2-mutant intracranial tumor model
Abstract: B168, Location: Session B, Hall C-D
Saturday, November 7, 2015, 12:30 PM to 3:30 PM
A mouse avatar tumor maintenance study identified a subset of SCLC patient-derived tumor xenograft models sensitive to the PARP inhibitor niraparib
Abstract: B169, Location: Session B, Hall C-D
Niraparib is an orally active and potent poly (ADP-ribose) polymerase, or PARP, inhibitor. A Phase 1/2 monotherapy study of niraparib has been completed in more than 100 patients with advanced solid tumors. Two Phase 3 trials are currently ongoing to evaluate a single oral dose of niraparib for patients with ovarian cancer and for patients with BRCA-positive breast cancer.
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding our optimism regarding niraparib's potential in multiple tumor types and our plans to initiate further clinical trials of niraparib. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the execution and completion of clinical trials, uncertainties surrounding the timing of availability of data from our clinical trials, ongoing discussions with and actions by regulatory authorities, patient accrual rates for clinical trials, and other matters that could affect the timing of availability of data from or initiation of our clinical trials, uncertainties regarding regulatory approvals, and other matters that could affect the potential of our drug candidates. TESARO undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see TESARO's Annual Report on Form 10-K for the year ended December 31, 2014 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015.
CONTACT: Investor/Media Contact: Jennifer Davis Sr. Director, Corporate Development & Investor Relations +1.781.325.1116 or email@example.com